Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis

NCT02312206 is registered in ClinicalTrials.gov with Prothena Biosciences Ltd. as lead sponsor.

NCT NCT02312206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02312206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Lead sponsor
Prothena Biosciences Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2015
Completion date
May 31, 2018
Enrollment
260 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

primary systemic (al) amyloidosis